A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18 (SB- 485232) Administered by Intravenous Infusion in Combination With Rituximab in Adult Patients With B Cell Non-Hodgkin's Lymphoma.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Iboctadekin (Primary) ; Rituximab
Indications B-cell lymphoma
Focus Adverse reactions; Biomarker
Sponsors GSK

Most Recent Events

04 Feb 2011 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
04 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
09 Oct 2008 Planned end date changed from May 2009 to 1 Nov 2008, based on information from ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight